Charles Schwab’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-1,567
Closed -$50.5K – 3605
2022
Q4
$50.5K Hold
1,567
– – ﹤0.01% 3357
2022
Q3
$66K Sell
1,567
-4,396
-74% -$201K ﹤0.01% 3272
2022
Q2
$252K Sell
5,963
-4,287
-42% -$199K ﹤0.01% 3214
2022
Q1
$695K Buy
10,250
+167
+2% +$13.9K ﹤0.01% 2991
2021
Q4
$1.23M Buy
10,083
+349
+4% +$58.9K ﹤0.01% 2837
2021
Q3
$1.37M Buy
9,734
+125
+1% +$24.8K ﹤0.01% 2779
2021
Q2
$2.64M Buy
9,609
+1,089
+13% +$275K ﹤0.01% 2620
2021
Q1
$1.82M Buy
8,520
+1,892
+29% +$523K ﹤0.01% 2690
2020
Q4
$1.6M Sell
6,628
-586
-8% -$72.5K ﹤0.01% 2654
2020
Q3
$761K Buy
7,214
+3,544
+97% +$323K ﹤0.01% 2746
2020
Q2
$360K Buy
3,670
+258
+8% +$22.6K ﹤0.01% 2964
2020
Q1
$257K Buy
3,412
+51
+2% +$4.86K ﹤0.01% 2938
2019
Q4
$273K Sell
3,361
-442
-12% -$49.5K ﹤0.01% 2995
2019
Q3
$465K Buy
3,803
+1,598
+72% +$220K ﹤0.01% 2829
2019
Q2
$397K Buy
2,205
+154
+8% +$24.9K ﹤0.01% 2917
2019
Q1
$329K Buy
2,051
+24
+1% +$4.75K ﹤0.01% 2915
2018
Q4
$528K Buy
2,027
+829
+69% +$167K ﹤0.01% 2745
2018
Q3
$292K Buy
1,198
+69
+6% +$18.1K ﹤0.01% 3011
2018
Q2
$267K Buy
+1,129
New +$329K ﹤0.01% 3011

Other funds holding EVLO

Charles Schwab's EVLO Position: Q1 2023 in Review

Charles Schwab sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2023, closing a stake of 1,567 shares — an estimated $50.5K sold.

Charles Schwab first reported a position in EVLO in Q2 2018 and held it in 19 quarters. The position peaked at $2.64M in Q2 2021. 39 funds tracked by Wall St. Rank hold EVLO as of Q1 2023.

  • Charles Schwab reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Charles Schwab sold 1,567 Evelo Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $50.5K.
  • Charles Schwab first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 19 quarters.
  • Charles Schwab's Evelo Biosciences, Inc. Common Stock position peaked at $2.64M in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2023.

Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.